Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

– Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function –

LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company’s board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.

“Maha joins our Board at a pivotal moment for Alto, as we continue on our path and fulfill our ambition of redefining psychiatry with our precision pipeline in areas of persistent medical need,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “Throughout her distinguished career, Maha has been dedicated to advancing patient care through more personalized approaches to treatment. We believe her guidance and input will be invaluable as we work to make precision psychiatry a reality for patients, physicians, caregivers, and payers.”

Maha Radhakrishnan, M.D., recently served as group senior vice president and chief medical officer of Biogen, responsible for the worldwide medical function, until March 2024. Previously, Dr. Radhakrishnan was senior vice president and global head of medical, primary care business unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the function providing the medical strategy for the diabetes and cardiovascular products and programs in development. Prior, she held several leadership roles at Bioverativ Inc., Bristol Myers Squibb, United Health Group, and Cephalon. Dr. Radhakrishnan received her M.D. in internal medicine with honors from the People’s Friendship University in Moscow, Russia in 1995, as well as a master’s degree in Russian language.

“The emergence of precision psychiatry is critically important given the urgent need to address the disparities in individual responses across treatments in mental healthcare,” added Dr. Radhakrishnan. “I am honored to join Alto’s board at such an exciting time in the company’s journey and I am encouraged by the data that has been exhibited across the company’s programs to date. I believe successful stratification of patients can unlock the ability to redefine psychiatric care in a truly meaningful way and Alto’s Precision Psychiatry Platform has the potential to pioneer this transformation.”

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations concerning Dr. Radhakrishnan’s contributions to its Board of Directors and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including the risk that Alto’s expectations concerning the appointment of Dr. Radhakrishnan to its Board of Directors may not be realized, and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in Alto’s Final Prospectus filed with the Securities and Exchange Commission (“SEC”) on February 5, 2024, pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

Contacts

Investor Contact
Nick Smith

[email protected]

Media Contact
Jordann Merkert

[email protected]